Advances in therapy of intermediate-or high-grade nonHodgkin's lymphomas (NHL) and Hodgkin's disease (HD) are one of the most important breakthroughs in oncology.
One possible way to improve results of HDT is with nonto be safe: carboplatin 1500 mg/m 2 , etoposide 2400 mg/m 2 and ifosfamide 10 g/m 2 . All patients developed crossresistant drugs which were not used during first-line and salvage treatment. They should have low non-hematograde 3 nausea and grade 3 or 4 mucositis. Granulocytopenic fever occurred in 100% with grade 4 infeclogic toxicity even in escalated doses. The topoisomerase II inhibitor etoposide has become one of the most effective tions in 15%. Mild transient kidney toxicity was noted in 36% and liver toxicity in 20% of patients. One toxic drugs for the treatment of NHL. Its synergism with alkylating agents and its limited non-hematologic toxicity makes death occurred (2.5%). Objective responses were obtained in 36 of 39 patients (92%) with complete it useful for combination in HDT. 9, 10 Ifosfamide is an oxazaphosphorine alkylating agent with a broad spectrum of remissions (CR) in 24 patients (61.5%) and partial remissions (PR) in 12 (30.7%). Median observation antineoplastic activity producing favorable response rates, for example, in germ cell cancer, ovarian carcinoma, NHL time for surviving patients was 23.3 months (range 3.4-52.3). The probabilities of overall, event-free and and HD. With uroprotection, the dose-limiting toxicity of ifosfamide is myelosuppression and neurotoxicity in relapse-free survival at 2 years are 62, 39 and 55%, respectively. Patients with primary refractory disease approximately 10-20%. In tumor models, there are indications for non-crossresistance with other nitrogen mustard or resistant relapse had a poor prognosis. High-dose carboplatin, etoposide and ifosfamide plus autologous compounds and for synergy with cisplatin. 11, 12 Carboplatin, a platinum compound with low nephrotoxicity as compared stem cell rescue represents an effective, potentially curative salvage treatment with acceptable toxicities.
with cisplatin, has been studied in several malignancies and in dose-escalation trials, especially in the treatment of tesKeywords: non-Hodgkin's lymphoma; Hodgkin's disease; high-dose chemotherapy; toxicity ticular cancer. This drug is a suitable agent for HDT because its main toxicity is also myelosuppression and because non-hematological adverse effects such as nephroand ototoxicity are low. 13,14 Therefore, we started a phase I/II study with high-dose carboplatin, etoposide, ifosfamide and autologous bone marrow (ABMT) or peripheral blood stem cell transplantation (PBSCT) as consolidation of remission to identify a regimen with broad-spectrum anti- responses to salvage therapy and three were transplanted CFU/kg). Two patients received PBSCs in addition to bone in more than second relapse without further response to marrow because of a poor bone marrow harvest (0.3 ϫ 10 8 conventional treatment. There were 16 cases with HD and MNC/kg or 0.9 ϫ 10 4 CFU/kg; and 7.7 ϫ 10 8 MNC/kg or 24 with NHL. At the time of relapse, 16 patients presented 13.3 ϫ 10 4 CFU/kg, respectively). with extranodal disease mostly involving the lungs (n = 9). Other sites were liver, spleen, kidneys, pleura, thyroid
Chemotherapy and supportive care gland, skin and bone. Ten patients had evidence of bulky disease at the time of relapse as shown in Table 1 . Overall, Salvage therapy was not uniform in all patients. Most 95% of patients had received at least two prior chemoreceived either two to three cycles of DexaBEAM (nine therapy regimens and 87% had received radiation to patients) or four to six cycles of CEIP with carboplatin, involved sites (radiation to the mediastinum in 55% of all etoposide, ifosfamide and prednisone (12 patients). Further patients) at any time during their disease.
regimens used were CHOP, CEVD, MACOP-B, IMVP-16 and ACOMeD. Pretransplantation preparative therapy consisted of one cycle of high-dose carboplatin, etoposide and Marrow and peripheral stem cell collection ifosfamide (Table 2) , administered during a 4-day period, followed by marrow or PBSC infusion on day 0. CarboplaAll patients had either a bone marrow harvest or peripheral blood stem cell (PBSC) collection after conventional tin and etoposide were given as a 60-min infusion once daily; ifosfamide was administered as a continuous infusion chemotherapy and G-CSF stimulation. Cryopreservation in 955 Table 2 CEI administration schedule
Response criteria
All patients were assessed for response 6 and 12 weeks у25% increase in pre-existing tumor or the appearance of any new lesion. Patients who died prior to the first restaging were not considered assessable for response. Toxicity was graded according to WHO criteria. over 22 h with mesna for uroprotection. Based on pre-existing data about dose-limiting toxicities of carboplatin and ifosfamide in the high-dose setting 14,16 and our own experiStatistical methods ences with the CEI-regimen in the treatment of patients with germ cell tumors, we used fixed doses of carboplatin Calculations of probabilities were performed using the lifeand ifosfamide as denoted in Table 3 . Etoposide doses were table analysis according to the method of Kaplan and planned to be escalated in steps of 400 mg from 1200
Meier. 18 Survival time was calculated from the date of stem mg/m 2 to MTD every six patients (Table 3) . At dose level cell transplantation to the date of death or last follow-up. 4 we stopped further escalation because of one early death Time of event-free survival was considered to begin with and evidence from another study that higher doses might documentation of CR and to end with the date of relapse, cause unacceptable toxicity. 17 death or last follow-up. Patients who did not achieve CR Patients were nursed in reverse-barrier isolation from the were included with an event-free survival of 0 days. start of conditioning until leukocyte counts exceeded
Patients who died in CR were censored at the time of death. 1000/l. They received 300 mg of allopurinol orally daily on days −7 to −1 and hydration with 2000 ml/m 2 plus NaHCO 3 if urine pH was below 7. Ciprofloxacin 250 mg Results three times per day and amphotericin B suspension 2400 mg orally daily were administered as antibacterial and antiHematologic toxicity and recovery fungal prophylaxis. Onset of fever (Ͼ38°C) was managed empirically with double-lactam antibiotic combination Stem cell rescue was bone marrow for 18 patients (45%), treatment. Vancomycin and intravenous amphotericin B PBSCs for 20 (50%), and a combination of both in two were added after 3 to 4 and 7 to 10 days, respectively, when cases (5%). One of the patients receiving bone marrow had fever did not abate. The antibiotic regimen was modified a syngeneic transplant. All patients at all dose levels according to microbiologic findings and clinical requireshowed complete hematological recovery, except one who ments. Total parenteral nutrition was given during periods died on day +15 before engraftment. Granulocyte recovery of inadequate oral intake. Twenty-eight patients (70%) to у0.5 ϫ 10 9 /l and platelet recovery to у20 ϫ 10 9 /l withreceived recombinant G-CSF or GM-CSF as a continuous out support took a median of 13 days (range, 7-31) and 16 intravenous infusion starting on day +1 until granulocytes days (range, 8-38), respectively. After discontinuation of recovered to у1000/l. Platelets were transfused to maingrowth factors only a slight to moderate decrease of tain platelet counts above 15 to 20 ϫ 10 9 /l (HLA-A and granulocyte counts, not requiring reinstitution of G-CSF, -B-matched single-donor concentrates), RBCs were transwas observed. For all patients, the median time to discharge fused to maintain hemoglobin levels between 52 and 65 was 20.6 days following marrow or PBSC infusion (range, mmol/l. All blood products were irradiated with 25 Gy.
9-56 days). and neutropenic fever were observed in all patients at all dose levels and all patients required parenteral nutrition. At No. of patients died from a road accident. Thirteen of 39 patients (33.3%) (dose level 4) a somewhat higher rate of toxicity occurred, are in ongoing CR, lasting longer than 2 years in nine with grade 4 infections in three of 19 patients (15%). One patients (23%); 24 patients (61.5%) relapsed or progressed poor-risk patient (NN) acquired pneumonia requiring mechfrom PR a median of 5.3 months (range, 1.9-27.2), mostly anical ventilation; the initial diagnosis was high-grade NHL at sites of previous disease. One, a patient with Burkitt's with bulky disease of the mediastinum, infiltration of the lymphoma, relapsed 4 months after HDT but achieved a left lung and atelectasis; he had previously received seven third CR with a pediatric B-NHL regimen. Thereafter, he cycles of CHOEP, involved field irradiation with 30 Gy received a second HDT with the BEAM regimen followed and two cycles of DexaBEAM with only a PR prior to by autotransplantation and has remained in continuous CR HDT. Another patient (AE) had septicemia with hypotenfor at least 19 months. The actuarial overall survival and sion and one patient (JR) experienced aspergillus pneuevent-free survival rates at 2 years are 62 and 30%, respectmonia (see 'Treatment-related deaths'). Liver toxicity was ively ( Figure 1 ). There is no significant difference in overall present in four patients (20%) with one WHO grade 3 and and event-free survival between patients with HD or NHL one grade 4 toxicity. Renal impairment with creatinine elevations Ͼ115 mol/l was noted in four patients (20%; creatinine max 133, 150, 230 and 389 mol/l). As at lower dose levels, all creatinine elevations were reversible and hemodialysis was not necessary. No acute or long-term CNS or peripheral neurotoxicity were noted.
Non-hematologic toxicity

Treatment-related deaths
One of 40 patients (2.5%) assessable for toxicity at dose level 4 died of procedure-related complications. He died of aspergillus pneumonia and liver failure on day +15. He had HD in 4th relapse and was heavily pretreated with four regimens and 36 Gy involved field irradiation of the phoma and transaminase levels of 100 U/l.
( Figure 2 ). The relapse-free survival rate for all patients of 20 patients (15%), grade 3 and 4 liver toxicity in 10% (two of 20 patients) with one hepatic failure, and transient achieving CR is 55% at 2 years. To date, we have observed one late relapse beyond 24 months after ASCR. Further renal impairment (grade 2 and 3) in 10% not requiring hemodialysis. Procedure-related mortality was 2.5%. Therefore, analysis, ie, differences between patients with sensitive or refractory relapse, is not possible because of the small size we stopped further dose escalation beyond 2400 mg/m 2 etoposide. While this study was in progress Wilson et al 22 of subgroups. Three patients with sclerosing B-NHL of the mediastinum did badly with only marginal and short-lived published their experience with identical drugs in patients with solid tumors and lymphomas. Noticeable toxicities responses to several salvage regimens and to HDT. Also, three of the four patients with primary refractory disease were: Ͼ50% loss of renal function in 11%, marked diarrhea, neurotoxicity, liver function abnormality and had a poor outcome. With HDT, they only achieved a PR lasting 2, 3 and 3 months. All died from progressive distreatment-related death in 7.3%. The lack of significant CNS toxicity in our study may be due to the relatively low dose of ifosfamide used compared tively high rate of interstitial pneumonitis or veno-occlusive disease, 6, 19 our goal was to find a regimen with less toxic with the studies mentioned above. Serum creatinine elevations occurred in 16% of patients in our study with no effects and comparable response rates. Etoposide and ifosfamide are well-established in high-dose settings, whereas chronic loss of renal function. This may only partly be due to lower carboplatin doses, because the dosage of carboplacarboplatin had been investigated to a much lesser extent. , carboplatin 400-1600 mg/m 2 ). Mild to moderate peripheral neurotoxicity and ototoxicity cer are often heavily pretreated with cisplatin-containing regimens which are known to cause renal impairment. In was observed at the 1600 mg/m 2 dose level of carboplatin. The incidence of renal impairment appeared to be higher this study of patients with malignant lymphomas, none was pretreated with cisplatin containing therapies, so that prewith the combination and related to the dose of carboplatin.
Based on these pre-existing data and our own experitreatment in patients with solid tumors possibly accounts for the higher degree of renal insufficiency. This may also ences in the treatment of germ cell tumors we used fixed levels of ifosfamide and carboplatin (10 g/m 2 and 1500 be due to the observed high incidence of skin toxicity in patients with testicular cancer. Treatment-related mortality mg/m 2 , respectively) with escalating doses of etoposide (1200 to 2400 mg/m 2 ). In our study, overall toxicity was was below 10% in all studies. No interstitial pneumonitis or veno-occlusive disease was observed in our study, which tolerable at all dose levels. At dose level 4 we saw lifethreatening toxic effects due to grade 4 infections in three is a major problem in HDT using TBI or nitrosoureacontaining regimens. [25] [26] [27] However, one has to be cautious when comparing MTDs of identical drug combinations determined in different studies, because MTD depends on various factors such as type of disease, stage, intensity and drugs used in prior treatments. Moreover, the sequence and mode of application of cytostatic drugs in high-dose settings as well as peculiarities of supportive treatment such as choice of antibiotics, have to be considered. Hematologic recovery was complete in all patients and no graft failure was noted. Time for granulocyte and platelet recovery was in the same range as reported by others. There was no significant difference between bone marrow and peripheral stem cell support. Hematopoietic growth factors became commercially available during the course of this study. Thus, the first 11 patients treated did not receive growth 
